Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 3/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.44 |
| ▸ | WNT3A | P56704 | 3/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715894 | 0.79 | POLQ (0.47) | POLQ | |
| SCHEMBL4028551 | 0.73 | KMO (0.52) | TRPV1PDK2SCN9ASCN5A | |
| SCHEMBL30704714 | 0.73 | KMO (0.52) | TRPV1PDK2SCN9ASCN5A | |
| SCHEMBL1177086 | 0.73 | CA2 (0.48) | WNT3A | |
| SCHEMBL1395805 | 0.72 | POLQ (0.55) | POLQ | |
| SCHEMBL4026680 | 0.72 | NOTUM (0.54) | PDK2 | |
| SCHEMBL4025957 | 0.72 | KMO (0.51) | TRPV1PDK2SCN9ASCN5A | |
| SCHEMBL14562998 | 0.71 | POLQ (0.56) | POLQ | |
| Hydrochloric Acid SCHEMBL8413702 | 0.71 | POLQ (0.54) | POLQ | |
| SCHEMBL4023458 | 0.71 | NOTUM (0.52) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
| WO-2004022534-A1 | ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS | NPS ALLELIX CORP. (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | POLQ 4449/4885NTRK1 3235/4885WNT3A 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.